Literature DB >> 15850793

SOCS-1 inhibits expression of the antiviral proteins 2',5'-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29.

Stephan Brand1, Kathrin Zitzmann, Julia Dambacher, Florian Beigel, Torsten Olszak, George Vlotides, Sören T Eichhorst, Burkhard Göke, Helmut Diepolder, Christoph J Auernhammer.   

Abstract

Recently, we have shown that SOCS-1/3 overexpression in hepatic cells abrogates signaling of type I interferons (IFN) which may contribute to the frequently observed IFN resistance of hepatitis C virus (HCV). IFN-lambdas (IL-28A/B and IL-29), a novel group of IFNs, also efficiently inhibit HCV replication in vitro with potentially less hematopoietic side effects than IFN-alpha because of limited receptor expression in hematopoietic cells. To further evaluate the potential of IFN-lambdas in chronic viral hepatitis, we examined the influence of SOCS protein expression on IFN-lambda signaling. First, we show that hepatic cell lines express the IFN-lambda receptor complex consisting of IFN-lambdaR1 (IL-28R1) and IL-10R2. Whereas in mock-transfected HepG2 cells, IL-28A and IL-29 induced STAT1 and STAT3 phosphorylation, overexpression of SOCS-1 completely abrogated IL-28A and IL-29-induced STAT1/3 phosphorylation. Similarly, IL-28A and IL-29 induced mRNA expression of the antiviral proteins 2',5'-OAS and MxA was abolished by overexpression of SOCS-1. In conclusion, we assume that despite antiviral properties of IFN-lambdas, their efficacy as antiviral agents may have similar limitations as IFN-alpha due to inhibition by SOCS proteins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15850793     DOI: 10.1016/j.bbrc.2005.04.004

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  33 in total

Review 1.  Interferons: Success in anti-viral immunotherapy.

Authors:  Fan-ching Lin; Howard A Young
Journal:  Cytokine Growth Factor Rev       Date:  2014-07-29       Impact factor: 7.638

2.  Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons.

Authors:  Jieliang Li; Shuxian Hu; Lin Zhou; Li Ye; Xu Wang; Jie Ho; Wenzhe Ho
Journal:  Glia       Date:  2010-09-27       Impact factor: 7.452

3.  Methylation and microRNA-mediated epigenetic regulation of SOCS3.

Authors:  Chandra S Boosani; Devendra K Agrawal
Journal:  Mol Biol Rep       Date:  2015-04       Impact factor: 2.316

Review 4.  Contribution of type III interferons to antiviral immunity: location, location, location.

Authors:  Sergei V Kotenko; Joan E Durbin
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

5.  New antiviral therapies for chronic hepatitis C.

Authors:  Tatsuo Kanda; Fumio Imazeki; Osamu Yokosuka
Journal:  Hepatol Int       Date:  2010-08-19       Impact factor: 6.047

6.  Quantitative analysis of interferon alpha receptor subunit 1 and suppressor of cytokine signaling 1 gene transcription in blood cells of patients with chronic hepatitis C.

Authors:  Virginia Sedeño-Monge; Gerardo Santos-López; Rosa C Rocha-Gracia; Daniel Meléndez-Mena; Alberto Ramírez-Mata; Verónica Vallejo-Ruiz; Julio Reyes-Leyva
Journal:  Virol J       Date:  2010-09-18       Impact factor: 4.099

7.  Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.

Authors:  Joshua M DiNapoli; Baibaswata Nayak; Lijuan Yang; Brad W Finneyfrock; Anthony Cook; Hanne Andersen; Fernando Torres-Velez; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

8.  Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.

Authors:  Jordan J Feld; Santosh Nanda; Ying Huang; Weiping Chen; Maggie Cam; Susan N Pusek; Lisa M Schweigler; Dickens Theodore; Steven L Zacks; T Jake Liang; Michael W Fried
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

9.  Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease.

Authors:  Julia Dambacher; Florian Beigel; Julia Seiderer; Dirk Haller; Burkhard Göke; Christoph J Auernhammer; Stephan Brand
Journal:  Gut       Date:  2007-04-20       Impact factor: 23.059

10.  Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication.

Authors:  Nicole E Pagliaccetti; Roger Eduardo; Steven H Kleinstein; Xinmeng Jasmine Mu; Prasanthi Bandi; Michael D Robek
Journal:  J Biol Chem       Date:  2008-08-29       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.